. Author manuscript; available in PMC: 2008 Oct 7.

Published in final edited form as: Biochim Biophys Acta. 2006 Oct 18;1772(4):446–456. doi: 10.1016/j.bbadis.2006.10.007

Table 1.

Cell-cycle mediators tested for modification of tau-induced neurodegeneration phenotypes

Cell-cycle mediator	System^*	Interaction with tau^**
UAS-Dacapo/UAS-Rbf1	Ret, Br	Sup
UAS-Dacapo/UAS-Cdk1^DN	Ret, Br	Sup
Cyclin A^LOF	Ret	Sup
Cyclin B^LOF	Ret	Sup
Cyclin B3^LOF	Ret	Sup
E2f1^LOF	Ret	Sup
Cyclin D^LOF	Ret	Sup
Cdk4^LOF	Ret	Sup
Cyclin E^LOF	Ret	None
UAS-Cyclin A	Ret, Br	Enh
UAS-Cyclin B	Ret, Br	Enh,(Ret), Lethal (Br)
UAS-Cyclin B3	Ret, Br	Enh,(Ret), Lethal (Br)
UAS-Cdk1, UAS-Cyclin B	Ret, Br	Enh,(Ret), Lethal (Br)
UAS-Cdk4, UAS-Cyclin D	Ret, Br	Enh,(Ret), Semilethal (Br)
UAS-Cyclin E	Ret, Br	Enh(Ret), Lethal (Br)
UAS-Cdk1	Ret	None
UAS-Cdk2	Ret	None

Retina (Ret; driver: GMR-GAL4), Brain (Br; driver: elav-GAL4)

^**

Synergistic Enhancement (Enh), Suppression (Sup) of tau-induced neurodegeneration, No effect (None), Lethal/Semilethal combination when co-expressed (Lethal, Semilethal).

Abbreviations: Dominant negative (DN), Loss-of-function allele (LOF); UAS (Upstream Activating Sequence) refers to GAL4-responsive transgenes.

Bold face indicate unexpected interactions.

Information regarding specific genetic reagents is published [46] or is available from the authors by request.